Understanding Nonalcoholic Steatohepatitis in Chinese Children
Nonalcoholic Steatohepatitis in Chinese Children: a Long Term Follow-up
Humanity and Health Research Centre · NCT03190538
This study looks at liver disease in Chinese children to see how it differs from adults and understand its effects on their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | Humanity and Health Research Centre (other) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT03190538 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate nonalcoholic steatohepatitis (NASH) in children, focusing on the histopathological features of pediatric nonalcoholic fatty liver disease (NAFLD). By analyzing biopsies and clinical data, the study seeks to document the prevalence and significance of various histological patterns in children, which may differ from those observed in adults. The goal is to better understand the natural history of NAFLD in the pediatric population and its potential implications for health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 1-18 with biopsy-proven nonalcoholic fatty liver disease.
Not a fit: Patients with viral hepatitis, autoimmune liver diseases, or liver impairment due to drugs will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of NASH in children, potentially reducing long-term health risks.
How similar studies have performed: While studies on adult NASH have been conducted, this specific focus on pediatric NASH and its histopathological features is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 1-18 with biopsy-proven NAFLD * Alcohol consumption less than 20g/day and 10g/day for boys and girls respectively Exclusion Criteria: * with viral hepatitis, e.g. HBV, HCV * with a1-anti-trypsin disease * with autoimmune hepatitis * with Wilson disease * with liver impaired by drugs
Where this trial is running
Beijing
- Children's Liver Disease Center, 302 Hospital — Beijing, China (RECRUITING)
Study contacts
- Principal investigator: George Lau, MD, PhD — Humanity and Health Medical Centre
- Study coordinator: George Lau, MD, PhD
- Email: gkklau@hnhmgl.com
- Phone: 852-28613777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-Alcoholic Fatty Liver Disease